Cerevance — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CVN424 150 mgThis is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.	Parkinson	Phase 3	À vérifier	United States, Australia, Czechia, France, Italy, Poland, Puerto Rico, Spain, …	À vérifier
CVN424 75 mgThis is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.	Parkinson	Phase 3	À vérifier	United States, Australia, Czechia, France, Italy, Poland, Puerto Rico, Spain, …	À vérifier
CVN424 75 mgThis is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.	Parkinson	Phase 3	À vérifier	United States, Australia, Czechia, France, Italy, Poland, Puerto Rico, Spain, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
CVN424 75 mg	Parkinson	Phase 3	NCT06553027	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	ACTIVE_NOT_RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
CVN424 150 mg		CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.	EClinicalMedicine
CVN424 75 mg		A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.	The Journal of pharmacology and experimental therapeutics